Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications.
about
Validation of biomarkers to predict response to immunotherapy in cancer: Volume I - pre-analytical and analytical validationDelayed effects of developmental exposure to low levels of the aryl hydrocarbon receptor agonist 3,3',4,4',5-pentachlorobiphenyl (PCB126) on adult zebrafish behavior.The genomic landscape of tuberous sclerosis complexEstablishing a human renal cell carcinoma tumorgraft platform for preclinical drug testingMethods and compositions for amplification and detection of microRNAs (miRNAs) and noncoding RNAs (ncRNAs) using the signature sequence amplification method (SSAM).Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.An integrative somatic mutation analysis to identify pathways linked with survival outcomes across 19 cancer types.Targeting renal cell carcinoma with a HIF-2 antagonist.Unique epigenetic gene profiles define human breast cancers with poor prognosis.Single-Cell mRNA Sequencing in Cancer Research: Integrating the Genomic Fingerprint.Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma.Modeling Renal Cell Carcinoma in Mice: Bap1 and Pbrm1 Inactivation Drive Tumor Grade.The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.Early Life Exposure to Low Levels of AHR Agonist PCB126 (3,3',4,4',5-Pentachlorobiphenyl) Reprograms Gene Expression in Adult Brain.Regulation of Fn14 Receptor and NF-κB Underlies Inflammation in Meniere's Disease.Isotachophoresis for fractionation and recovery of cytoplasmic RNA and nucleus from single cells.Transcription factors Tp73, Cebpd, Pax6, and Spi1 rather than DNA methylation regulate chronic transcriptomics changes after experimental traumatic brain injury.
P2860
Q28075719-44F4F280-D885-4B57-A05A-F73C0D4BAEE1Q30711723-45AB1B1C-5D0F-44DB-A00B-7EA262CA2F51Q33826893-2EF6AC30-361D-40E6-966F-8EED53ADA6BFQ35041892-FFADC7AB-2C53-400E-84C8-8706F88AF253Q35064639-732F9003-53E4-4B00-A016-524558AECBE0Q35810625-575FAA41-5D35-4532-88CC-050CB2521D8EQ36967202-44E6B808-5BC1-4D63-80A6-68B1242911ECQ37684974-40E552DB-A7DC-4F07-AAB9-06484BCDBDD2Q37699138-AE19AFE2-C6C0-4DEA-A1EB-9619DD3217C6Q39377159-C79F73D2-844B-4C84-AB2A-6B50F849C4F7Q39798868-9DD6A5E4-DC64-4B03-88DF-E1F0CCBEE15FQ46856592-0F605A41-8E98-41C9-A074-444DEE35F187Q47757165-B053612C-9219-4495-836B-A4D2E7BF8C4FQ48035326-0E4A2246-0B41-49E9-8A09-B9C2F486EE21Q49412683-DB956D98-E83F-4BA2-A6FD-4096733BEE8AQ51496512-4EB2560D-90FB-4364-953C-53DE7B8FC791Q55247467-9B46FB0A-7114-4F8C-9CC5-A96C743A41F0
P2860
Simultaneous isolation of high-quality DNA, RNA, miRNA and proteins from tissues for genomic applications.
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Simultaneous isolation of high ...... sues for genomic applications.
@ast
Simultaneous isolation of high ...... sues for genomic applications.
@en
Simultaneous isolation of high ...... sues for genomic applications.
@nl
type
label
Simultaneous isolation of high ...... sues for genomic applications.
@ast
Simultaneous isolation of high ...... sues for genomic applications.
@en
Simultaneous isolation of high ...... sues for genomic applications.
@nl
prefLabel
Simultaneous isolation of high ...... sues for genomic applications.
@ast
Simultaneous isolation of high ...... sues for genomic applications.
@en
Simultaneous isolation of high ...... sues for genomic applications.
@nl
P2860
P356
P1433
P1476
Simultaneous isolation of high ...... sues for genomic applications.
@en
P2093
James Brugarolas
P2860
P2888
P304
P356
10.1038/NPROT.2013.141
P577
2013-10-17T00:00:00Z
P5875
P6179
1010156526